- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Samsung Gets FDA Nod on New Glass-Free Detector for X-Ray Use
The AccE Glass-Free Detector reportedly combines high-resolution capability with a variety of benefits including improved functionality, enhanced visibility, and a lightweight design.
Emphasizing strong image quality and a portable lightweight design, Samsung has unveiled the new AccE Glass-Free Detector, which recently garnered 510(k) clearance from the Food and Drug Administration (FDA).
Samsung said the 4.5-lb. AccE Glass-Free Detector is 27 percent lighter than conventional X-ray detectors and offers a 76 percent detective quantum efficiency (DQE), according to the company.
The design of the device also reportedly facilitates patient comfort and positioning. Noting compatibility with Samsung’s AccE GM85 mobile digital radiography system, Samsung said the AccE Glass-Free Detector features a side chamfer to assist with lifts, a rear grip for smoother transportation and a flexible panel with center engraving to assist with patient positioning. The device also has a robust load allowance with the capacity to hold up to 881 pounds of surface load and 441 pounds of patient load, according to Samsung.
“We have recognized the need for new solutions that enhance both patient and user comfortability,” noted David Legg, the vice president and head of Boston Imaging, the United States headquarters for Samsung’s digital radiography and ultrasound business. “From the ER to the OR, our glass-free detector exhibits reliability in versatile environments to help get the job done.”
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.
